30 results about "Hepatectomy" patented technology

Lumenectomy material is tested to determine the presence or likelihood of a condition of a patient. The lumenectomy material is in the form of at least one continuous tissue strand collected in vivo from an inner surface of a body lumen of the patient. The presence of at least one marker of a disease is determined. The disease may be hypertension, hyperlipidemia, depression, obesity, metabolic syndrome, insulin resistance, kidney damage, or diabetes. The patient is identified as having or as likely to develop the disease if a marker of the disease is identified in the lumenectomy material of the patient.

The invention discloses an in vitro construction method of liver organs and applications. Mouse hepatocytes are extracted to induce to construct liver organs; the forms of the liver organs are observed under a microscope; and immunofluorescence and PCR identification are performed on dryness and epithelial cell properties. An acute hepatic failure mouse model after 70% hepatectomy is established;the liver functions on the first, fourth and seventh day after operation are evaluated after the liver organs are transplanted; liver-to-body ratio is compared; and the treatment effects of the liverorgans on acute hepatic failure are verified through HE staining and immunohistochemistry. Inflammations such as HE staining and ki-67 staining and proliferation indexes show that proliferation can beobviously enhanced after the liver organs are transplanted. The liver organs have strong dryness and proliferation functions; the liver functions of acute hepatic failure mice after 70% hepatectomy can be effectively relieved, and the liver-to-body ratio can be increased; and liver regeneration and repair of acute hepatic failure after 70% hepatectomy can be promoted by relieving inflammatory infiltration of livers.

An embodiment of the invention discloses an ultrasonic scalpel for hepatectomy and a use method of the ultrasonic scalpel, and particularly relates to the field of ultrasonic scalpels. The ultrasonicscalpel comprises a main machine, wherein a chassis is fixedly mounted at the bottom end of the main machine, a foot switch is arranged on one side of the main machine, the main machine is connected with the foot switch through a wire, a handle is arranged on one side of the main machine, a transducer is fixedly mounted at the top end of the handle, and a connecting pipe is arranged on one side ofthe transducer. By arrangement of a base, a mounting plate, a positioning block and second limiting rods, when a scalpel head is mounted, the base at one end of the scalpel head needs to be embeddedinto the mounting plate, and a positioning groove in the bottom end of the base is matched with the positioning block, then, the second limiting rods in inner grooves are attracted by second magneticblocks on an outer ring and move towards one side of the second magnetic blocks, the second limiting rods are inserted into clamping grooves in the two sides of the mounting plate to fix the base, andthe scalpel head thus can be mounted and dismantled by people conveniently.

The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of amino acid sequences represented by SEQ ID NOS: 1 to 22, or an amino acid sequence in which one to several amino acids are deleted, substituted or added at the amino acid residues other that the first to forth amino acid residues from the amino-terminus in the said amino acid sequence, or a pharmacologically acceptable salt thereof. The preventive or the therapeutic agent for hepatopathy in accordance with the present invention is useful as a drug suitable for treating or preventing hepatic diseases such as hepatitis, liver cirrhosis and hepatic insufficiency. Further, the preventive or the therapeutic agent for hepatopathy in accordance with the present invention is also useful as an agent of promoting hepatic regeneration and hepatic function recovery after hepatectomy.

The invention relates to a perivascular ring having an inner diameter adjustable by inflation / deflation and adapted to be implanted and closed about a vessel for controlling the inner diameter of said vessel and thus the flow and / or pressure of a fluid flowing in said vessel. The ring of the invention is capable of regulating blood flow to the liver, in particular after an hepatectomy or hepatic transplant, and to substantially improve the survival chances of the patient. The ring according the invention has an adjustable inner diameter (Øi) for implantation and locking about a vessel.

The invention discloses a recovery type medical formula food for liver cancer patients after hepatectomy. Main materials of the formula food consist of apios americana medikus as a basic material, and an additive, wherein the additive consists of glucose syrup, leucine, isoleucine, valine, arginine, linoleic acid, linolenic acid, pantothenic acid, VB12, VC, VE, VA, ferrous gluconate, sodium selenate, copper gluconate, calcium gluconate, zinc gluconate, sodium molybdate and chromium chloride. The invention also provides a preparation method of the formula food at the same time. The formula food can promote liver regeneration and enhance the immunity of patients.

The invention relates to a perivascular ring having an inner diameter adjustable by inflation / deflation and adapted to be implanted and closed about a vessel for controlling the inner diameter of said vessel and thus the flow and / or pressure of a fluid flowing in said vessel. The ring of the invention is capable of regulating blood flow to the liver, in particular after an hepatectomy or hepatic transplant, and to substantially improve the survival chances of the patient. The ring according the invention has an adjustable inner diameter (Oi) for implantation and locking about a vessel.

The invention relates to a perivascular ring having an inner diameter adjustable by inflation / deflation and adapted to be implanted and closed about a vessel for controlling the inner diameter of said vessel and thus the flow and / or pressure of a fluid flowing in said vessel. The ring of the invention is capable of regulating blood flow to the liver, in particular after an hepatectomy or hepatic transplant, and to substantially improve the survival chances of the patient. The ring according the invention has an adjustable inner diameter (φi) for implantation and locking about a vessel.

The invention discloses a method and device for generating a cutting surface in operation on liver. The method comprises: on the basis of a three-dimensional reconstruction model, data related to an infection focus in all hepatic segments are calculated; input information determined for a specified hepatic segment based on the data is received; and on the basis of the input information, a cuttingsurface for the operation on liver is generated. According to the invention, the data related to the focus size in each hepatic segment are obtained; the input information of overall cutting or partial cutting of the hepatic segments with the focus sizes larger than zero is received; a first cutting area and a second cutting area are generated based on the input information; and the cutting surface for the operation on liver is generated. Therefore, comprehensive judgment of the doctor is integrated to the generation process of the cutting surface; advantages of both the anatomical hepatectomyand precise hepatectomy are considered; and the subjectivity and instability of the manual operation are avoided.

The invention relates to a dynamic three-dimensional reconstruction method and system for hepatectomy. The dynamic three-dimensional reconstruction method comprises the following steps of obtaining initial grid data based on a preoperative CT (Computed Tomography) image; obtaining a two-dimensional projection image of an operation area by using intraoperative CT to obtain target grid data; constructing curved surface models by using the target grid data and the initial grid data, performing rigid registration, and delimiting a model curved surface part with a relatively large deformation area to be divided into a to-be-reconstructed space; performing non-rigid deformation on the initial grid area in the to-be-reconstructed space, and reconstructing a high-resolution curved surface model of the to-be-reconstructed space; and replacing a corresponding part of a preoperative total liver tissue precise three-dimensional curved surface model with the generated high-resolution curved surface model of the to-be-reconstructed space. Compared with the prior art, the method is advantaged in that problems of high time complexity, high computing power requirement and incapability of dynamically monitoring a local area in the prior art are solved, a curved surface of the liver tissue in the operation area is quickly reconstructed in the operation, and purposes of dynamically monitoring and assisting in precise excision in the operation process are achieved.

The present invention provides a method for isolating normal hepatocytes, the method comprising the steps of: recovering liver tissue from a patient during a hepatectomy; and isolating normal hepatocytes from unwanted cells present in the recovered tissue by magnetic separation. The invention further provides a method of preparing hepatocytes for transplantation, the method comprising the steps of: recovering liver tissue from a patient during a hepatectomy; and isolating normal hepatocytes from unwanted cells present in the recovered tissue by magnetic separation.

The invention relates to a perivascular ring having an inner diameter adjustable by inflation / deflation and adapted to be implanted and closed about a vessel for controlling the inner diameter of said vessel and thus the flow and / or pressure of a fluid flowing in said vessel. The ring of the invention is capable of regulating blood flow to the liver, in particular after an hepatectomy or hepatic transplant, and to substantially improve the survival chances of the patient. The ring according the invention has an adjustable inner diameter (Øi) for implantation and locking about a vessel.

The invention discloses a pair of vibrating liver forceps. The pair of vibrating liver forceps comprises a pair of hinged forceps bodies. A plurality of vibrating modules and absorption grooves are formed in a clamping face of each forceps body, the vibrating modules and the absorption grooves are distributed in a spaced manner, a vibrating device is arranged below the vibrating modules and is connected to a controller, and the absorption grooves communicate to a negative gas source. The vibrating liver forceps can be used for clamping liver in a large area to crush, so that the vibrating liver forceps have large simultaneous action areas, the working efficiency is improved greatly, the hepatectomy process is accelerated, the working strength of medical staff is reduced, and paint of the patient is alleviated.

With the present invention, liver cell function research of a human fetal liver cell line L-02 is performed, and the human fetal liver cell line L-02 is adopted in liver cell transplantation. The research results show that: the L-02 cells have good liver cell functions, can express a plurality of liver cell specificity factors, wherein the liver cell specificity factors comprise albumin, bilirubin glucuronosyltransferase, blood coagulation factors, transaminase and the like. 90% hepatectomy-induced acute liver failure (ALF) rat model experiment results show that: the survival time of the ALF rats can be effectively prolonged with the L-02 cells, the tumorigenesis risk does not exist, the L-02 cells is expected to be the good cell source for liver cell transplantation, bioartificial liver, medical researches related to the liver cell functions, and the like, and is applicable for treatment of the ALF, liver cell function researches, and other medical fields.

The invention relates to an immunohistochemical detection kit used for prognosis after hepatectomy. The immunohistochemical detection kit comprises a first antibody and a second antibody, the first antibody is two or combination of more than two selected from the following protein molecular markers of an antibody: CD33 (cluster of differentiation 33), CD11b (ITGAM), and CD169 (sialic acid adhesin). The kit employs a double antibody / tri-antibody combination index, prognosis condition of the patient after operation can be accurately predicted, so that appropriate treatment population and modes can be selected for doctors, and the kit provides more powerful support for effective diagnosis and treatment.

The present invention provides a method for isolating normal hepatocytes, the method comprising the steps of: recovering liver tissue from a patient during a hepatectomy; and isolating normal hepatocytes from unwanted cells present in the recovered tissue by magnetic separation. The invention further provides a method of prepuing hepatocytes for transplantation, the method comprising the steps of: recovering liver tissue from a patient during a hepatectomy; and isolating normal hepatocytes from unwanted cells present in the recovered tissue by magnetic separation.

The invention belongs to the technical field of medical instruments, and discloses an instrument table stand for protecting a patient's leg during an endoscopic or open surgery, and is provided with astand body; the stand body has a C-shaped structure, the upper end surface of the stand body is a support panel, and the lower end surface of the stand body is integrally formed three support strips;the stand body is a PVC material plate, a reinforcing keel is embedded in the stand body, and a sponge layer is adhered on the inner side of the stand body; three elastic bands are arranged in the middle of the stand body; both ends of the elastic band are respectively connected to the support panel and the three support strips by snaps. The instrument table stand can avoid the oppression of thepatient's leg by a mirror-bearing hand, reduce the arm fatigue of the mirror-bearing hand, can also be used as an instrument table, the structure is simple and flexible, the stand has multiple functions, is very suitable for the laparoscopic surgery and open surgery, and is suitable for various open surgery and endoscopic pancreaticoduodenectomy, hepatectomy, gastrointestinal resection, hysterectomy and other major operations.

The present invention discloses a set of genes for predicting the prognosis of liver cancer patients and liver cancer targeted therapy. Due to the lack of sufficient biomarkers in the prior art to predict the prognosis of liver cancer patients, especially for patients with advanced liver cancer, traditional The treatment methods such as liver transplantation, surgical hepatectomy, and early radiofrequency treatment are limited. Therefore, the exploration of new biomarkers is very important for the treatment target of liver cancer. The present invention further screened out the G2M test by COX survival analysis The point genes are concentrated on the genes related to the prognosis of liver cancer, and a model that affects the prognosis of liver cancer patients is constructed through multivariate COX survival analysis. The K-M plot curve, ROC curve, and the survival time and survival status of the patients all verify the accuracy and reliability of the model. Therefore, this prediction model has important significance for the prognosis and targeted therapy of patients with liver cancer.

The invention discloses application of resina draconis to preparation of a medicine for treating acute liver injury caused by hepatectomy. According to the application, resina draconis is extracted and purified with 85% ethanol twice and reduced-pressure recovery is performed to obtain fluid extract, the concentrate is spray-dried and screened by a 120-mesh screen to obtain resina draconis extract powder, the resina draconis extract powder is suspended in CMC-Na or dissolved with 1%-50% glycerol, filtering is performed by a 0.2mu m filter membrane to obtain a medicine preparation, the medicine preparation is orally administered or injected at a dosage of 0.1-5mg / kg weight, liver function index detection is performed to observe the liver tissue repairing condition, and the results show that the liver function is restored to be normal, so that the resina draconis has the effect of promoting the repairing of liver injury caused by hepatectomy.

Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia / reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and / or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia / reperfusion.

A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-S2 deletion mutant LHBS using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.

The invention discloses methylene blue temperature-sensitive hydrogel, preparation thereof, and an application thereof in anatomical hepatectomies. The methylene blue temperature-sensitive hydrogel is temperature-sensitive poly(glycolide-co-lactide)-polyethylene glycol-poly(glycolide-co-lactide) gel loaded with methylene blue. A preparation method of the methylene blue temperature-sensitive hydrogel comprises the following steps: synthesis of temperature-sensitive poly(glycolide-co-lactide)-polyethylene glycol-poly(glycolide-co-lactide) copolymer, preparation of blank gel, pretreatment of methylene blue, and preparation of the methylene blue temperature-sensitive hydrogel. The methylene blue temperature-sensitive hydrogel can be injected into a to-be-cut hepatic tissue through portal vein injection, and gradually forms a gelatinization state after reaching the in-vivo body, and achieves the slow release and positioning effects at the diseased region, and the to-be-cut hepatic tissue is dyed permanently, so that purpose of the accurate anatomical hepatectomies is achieved.

The present invention belongs to the technical field of medical devices and discloses an instrument table bracket used for protecting patient's legs in laparoscopic or open surgeries. The instrument table bracket is provided with a bracket main body; the bracket main body is a C-shaped structure, an upper end transverse plane of the bracket main body is a support panel and a lower end transverse plane of the bracket main body is three integrally formed support strips; the bracket main body is a PVC material plate, an inside of the bracket main body is embedded with a reinforcing keel, and an inside of the bracket main body is bonded with sponge layers; three elastic bands are arranged in a middle of the inside of the bracket main body, and both ends of the elastic bands are respectively connected with the support panel and the three support strips through buckles. The instrument table bracket can avoid oppression of the patient's legs by a mirror-supporting hand, reduces arm fatigue ofthe mirror-supporting hand, can also be used as an instrument table, is simple and flexible, has various uses, and is very suitable for applications in the laparoscopic surgeries and open surgeries,and suitable for horizontal-position various open surgeries and laparoscopic pancreaticoduodenectomy, hepatectomy, gastrointestinal resection, hysterectomy and other major surgeries.

Hyaluronic acid modified with sphingosine-1-phosphate, and a medicine comprising the hyaluronic acid as an active ingredient, wherein the medicine can alleviate hepatic disorder caused by hypoxia / reoxygenation by protecting the liver sinusoidal endothelial cells, and the medicine can prevent and / or treat liver failure due to liver transplantation, hepatectomy, or other surgeries associated with liver ischemia / reperfusion.

The invention discloses methylene blue temperature-sensitive hydrogel, preparation thereof, and an application thereof in anatomical hepatectomies. The methylene blue temperature-sensitive hydrogel is temperature-sensitive poly(glycolide-co-lactide)-polyethylene glycol-poly(glycolide-co-lactide) gel loaded with methylene blue. A preparation method of the methylene blue temperature-sensitive hydrogel comprises the following steps: synthesis of temperature-sensitive poly(glycolide-co-lactide)-polyethylene glycol-poly(glycolide-co-lactide) copolymer, preparation of blank gel, pretreatment of methylene blue, and preparation of the methylene blue temperature-sensitive hydrogel. The methylene blue temperature-sensitive hydrogel can be injected into a to-be-cut hepatic tissue through portal vein injection, and gradually forms a gelatinization state after reaching the in-vivo body, and achieves the slow release and positioning effects at the diseased region, and the to-be-cut hepatic tissue is dyed permanently, so that purpose of the accurate anatomical hepatectomies is achieved.

A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-S2 deletion mutant LHBS using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.

The invention provides an artificial blood vessel. The artificial blood vessel comprises a lower cavity vessel, a liver right vessel, a liver middle vessel and a liver left vessel, wherein the lower cavity vessel is provided with a first port located at the upper part and a second port located at the lower part, the first port is in coincidence and communication with the upper part stump of liverinferior vena cava or a right auricle, and the second port is in coincidence and communication with the lower part stump of the liver inferior vena cava; and the upper end of the liver right vessel, the upper end of the liver middle vessel and the upper end of the liver left vessel communicate with the lower cavity vessel, the lower end of the liver right vessel is in coincidence and communicationwith the stump of a liver right vein, the lower end of the liver middle vessel is in coincidence and communication with the stump of a liver middle vein, and the left end of the liver left vessel isin coincidence and communication with the stump of the liver left vein. Therefore, when a non in situ hepatectomy is performed, whole excision from the right auricle to a second hepatic portal in theliver is realized. The problem that in the prior art, a single-cavity straight artificial blood vessel is adopted, so that whole excision from the right auricle to the second hepatic portal in the liver cannot be realized in the process in a surgery, can be solved.

The invention discloses an in vitro construction method and application of liver organoids. Mouse hepatocytes are extracted to induce the construction of liver organoids, their morphology is observed under a microscope, and their stemness and epithelial cell attributes are identified by immunofluorescence and PCR. Establish a mouse model of acute liver failure after 70% hepatectomy, evaluate the liver function on the 1st, 4th, and 7th day after liver organoid transplantation, compare the liver-to-body ratio, and verify the effect of liver organoids on acute liver failure by HE staining and immunohistochemistry. Therapeutic effects in liver failure. Inflammation and proliferation indicators such as HE staining and ki-67 staining showed that the proliferation of liver organoids was significantly enhanced after transplantation. Liver organoids have strong dryness and proliferation function; they can effectively alleviate the liver function of mice with acute liver failure after 70% hepatectomy, increase the liver-to-body ratio, and promote acute liver failure after 70% hepatectomy by reducing liver inflammation infiltration. Liver regeneration and repair in liver failure.

The present invention relates to a preventive or a therapeutic agent for hepatopathy, comprising, as an effective ingredient, a polypeptide derivative having an activity of binding to growth hormone secretagogue receptor and thus elevating intracellular calcium ion concentration, and having one amino acid sequence selected from the group consisting of amino acid sequences represented by SEQ ID NOS: 1 to 22, or an amino acid sequence in which one to several amino acids are deleted, substituted or added at the amino acid residues other that the first to forth amino acid residues from the amino-terminus in the said amino acid sequence, or a pharmacologically acceptable salt thereof. The preventive or the therapeutic agent for hepatopathy in accordance with the present invention is useful as a drug suitable for treating or preventing hepatic diseases such as hepatitis, liver cirrhosis and hepatic insufficiency. Further, the preventive or the therapeutic agent for hepatopathy in accordance with the present invention is also useful as an agent of promoting hepatic regeneration and hepatic function recovery after hepatectomy.